What does VPI stand for?

Vasopeptidase Inhibitor

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Veterinary Public Health Unit (UK) Veterinary Public Health Workforce Expansion Act of 2007 Vaccine Preventable Diseases and Immunization Vacuum Pressure Impregnation (electrical coil manufacture) Valley Productions Inc (Tuscumbia, AL) Value Package Introduction Values Preference Indicator (consulting) Valve Position Indicator (Damcos) Vanishing Point Industries (Lansing, MI) Vapor Phase Inhibitor (paper)		Vegetation Productivity Indicator Velocity Profile Inversion Velopharyngeal Inadequacy Velopharyngeal Insufficiency Verilog Procedural Interface (computer programming) Vertical Print Inspection Very Profitable Item Veterinary Pet Insurance VGAP Player Index Viatron Programming, Incorporated

Samples in periodicals archive:

Omapatrilat is an investigational drug in a new class of cardiovascular medications, called vasopeptidase inhibitors (VPIs), which simultaneously inhibits two key enzymes that regulate heart function and blood pressure -- neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE).

OMAPATRILAT REDUCES RISK FOR CONGESTIVE HEART FAILURE PATIENT

Omapatrilat is the first and most clinically advanced vasopeptidase inhibitor, says John Kostis, MD, principal investigator of the study and chair of the department of medicine at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School in New Brunswick, NJ.

CHF drug trials are highlight of ACC 2000

Like standard ACE inhibitors, the vasopeptidase inhibitors block angiotensin converting enzyme, which raises blood pressure.

NEW DRUGS SHOW PROMISE IN REDUCING BLOOD PRESSURE